| Followers | 1436 |
| Posts | 30046 |
| Boards Moderated | 30 |
| Alias Born | 12/10/2012 |
Tuesday, June 17, 2025 9:34:49 AM
$ADIL: Added 30k here at $0.21................
Wow .......... you were here before me.
Not bad................ lets make some money here now.
GO $ADIL
Wow .......... you were here before me.
Not bad................ lets make some money here now.
GO $ADIL
Recent ADIL News
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans • GlobeNewswire Inc. • 03/24/2026 01:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:15:35 PM
- Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 10:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 01:17:24 PM
- Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement • GlobeNewswire Inc. • 03/03/2026 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 02:06:05 PM
- Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement • GlobeNewswire Inc. • 02/24/2026 02:00:00 PM
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 04:06:49 PM
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 09:30:34 PM
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 • GlobeNewswire Inc. • 02/04/2026 02:35:00 PM
- Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 • GlobeNewswire Inc. • 01/14/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 09:15:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/06/2026 09:15:31 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/23/2025 09:00:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/19/2025 10:10:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2025 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 09:05:52 PM
- Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds • GlobeNewswire Inc. • 11/26/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 01:35:25 PM
